DocGo Inc. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
DocGo Inc. (DCGO) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $580.50 thousand as of 2021-12-31, per its 10-K filed 2022-03-15.
Discontinued › Notes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2022-03-15
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $580.50K.
- 2020-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $622.98K.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2021-12-31 | $580.50K 10-K · filed 2022-03-15 |
| 2020-12-31 | $622.98K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |